Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer - PubMed (original) (raw)
Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer
P O Chappuis et al. Clin Genet. 2001 Jun.
Abstract
The frequency of BRCA1 and BRCA2 mutations in women with breast cancer varies according to the age at diagnosis, family history of cancer, and ethnicity/country of origin. We set out to estimate the frequency of seven previously described founder mutations in BRCA1 and BRCA2 in all eligible French Canadian women diagnosed with invasive breast cancer at one Montreal hospital over a 20-month period. One hundred and ninety-two patients were eligible and 127 (66.2%) provided blood for genetic testing. We identified 4 women who carried a founder mutation (3.1%, 95% confidence interval 0.9-7.9%) in this population. Interestingly, all the mutations were in BRCA2. The mean age at diagnosis for mutation carriers was 51.2 years (range 49.1-53.5). Two of these 4 cases were lobular invasive carcinomas and 2 were ductal carcinomas, histological grade 1 or 2. Despite a small tumor size (< or =20 mm), axillary nodal involvement was present in 3 women. Estrogen receptors were strongly expressed in all cases. Two of the 4 cases reported a strong family history of breast cancer, but a family history of site-specific breast cancer was a relatively poor indicator of the presence of BRCA2 mutations. The absence of BRCA1 mutations may be a result of chance, but may also reflect different geographical origins of the most common BRCA1 mutations within the French Canadian population.
Similar articles
- Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.
Tonin PN, Perret C, Lambert JA, Paradis AJ, Kantemiroff T, Benoît MH, Martin G, Foulkes WD, Ghadirian P. Tonin PN, et al. Int J Cancer. 2001 May 20;95(3):189-93. doi: 10.1002/1097-0215(20010520)95:3<189::aid-ijc1032>3.0.co;2-n. Int J Cancer. 2001. PMID: 11307153 - BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, Haas B, Norton L, Offit K. Robson M, et al. Cancer Res. 1998 May 1;58(9):1839-42. Cancer Res. 1998. PMID: 9581822 - [BRCA1 and BRCA2: mutations and other genetic changes--practical relevance].
Scherneck S, Hofmann W. Scherneck S, et al. Chirurg. 1999 Apr;70(4):373-9. doi: 10.1007/s001040050659. Chirurg. 1999. PMID: 10354832 Review. German. - The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era: historical perspectives.
van de Vijver MJ. van de Vijver MJ. Breast Cancer Res. 1999;1(1):27-30. doi: 10.1186/bcr9. Epub 1999 Oct 27. Breast Cancer Res. 1999. PMID: 11250679 Free PMC article. Review.
Cited by
- Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson AM, Foulkes WD, Ghadirian P, Provencher D, Tonin PN. Oros KK, et al. BMC Med Genet. 2006 Mar 15;7:23. doi: 10.1186/1471-2350-7-23. BMC Med Genet. 2006. PMID: 16539696 Free PMC article. - The contribution of inherited factors to the clinicopathological features and behavior of breast cancer.
Foulkes WD, Rosenblatt J, Chappuis PO. Foulkes WD, et al. J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):453-65. doi: 10.1023/a:1014791115760. J Mammary Gland Biol Neoplasia. 2001. PMID: 12013534 Review. - Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls.
Behl S, Hamel N, de Ladurantaye M, Lepage S, Lapointe R, Mes-Masson AM, Foulkes WD. Behl S, et al. Sci Rep. 2020 Apr 16;10(1):6491. doi: 10.1038/s41598-020-63100-w. Sci Rep. 2020. PMID: 32300229 Free PMC article. - The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families.
Fierheller CT, Alenezi WM, Tonin PN. Fierheller CT, et al. Cancers (Basel). 2021 Jul 7;13(14):3406. doi: 10.3390/cancers13143406. Cancers (Basel). 2021. PMID: 34298626 Free PMC article. Review. - Germline truncating mutations in both MSH2 and BRCA2 in a single kindred.
Thiffault I, Hamel N, Pal T, McVety S, Marcus VA, Farber D, Cowie S, Deschênes J, Meschino W, Odefrey F, Goldgar D, Graham T, Narod S, Watters AK, MacNamara E, Du Sart D, Chong G, Foulkes WD. Thiffault I, et al. Br J Cancer. 2004 Jan 26;90(2):483-91. doi: 10.1038/sj.bjc.6601424. Br J Cancer. 2004. PMID: 14735197 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous